Wie hoch ist der Preis für Timber Pharmaceuticals, Inc. (TMBR)

Preis für Timber Pharmaceuticals, Inc. (TMBR) ist $0.0101

Wie hoch ist die Marktkapitalisierung für Timber Pharmaceuticals, Inc. (TMBR)

Marktkapitalisierung für Timber Pharmaceuticals, Inc. (TMBR) ist $5.32K

Timber Pharmaceuticals, Inc. (TMBR) Kursverlauf

Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the research, development, and market introduction of treatments for rare dermatological conditions. The company's key product candidates include: TMB-001, a patented topical isotretinoin formulation, which has successfully completed Phase 2b clinical trials. It is designed to address moderate to severe forms of Congenital Ichthyosis (CI), a group of uncommon genetic disorders affecting skin keratinization. TMB-002, a proprietary topical rapamycin, currently undergoing Phase 2b clinical trials. This therapy targets facial angiofibroma associated with Tuberous Sclerosis Complex, a complex genetic disorder characterized by the growth of benign tumors in multiple organs. TMB-003, a unique Sitaxsentan formulation functioning as a selective endothelin-A receptor antagonist, which is in preclinical development for various sclerotic skin diseases. Additionally, through a licensing agreement with AFT Pharmaceuticals Limited, Timber Pharmaceuticals is advancing two topical minocycline therapies: BPX-01, now in Phase 3 development for treating inflammatory lesions of acne vulgaris. BPX-04, which is prepared for Phase 3 trials, targeting papulopustular rosacea. Founded in 2019, Timber Pharmaceuticals is headquartered in Basking Ridge, New Jersey.

Jahr	Leistung
2023	-94.17%
2022	-93.06%
2021	-56.86%
2020	-78.77%
2019	-87.10%
2018	1.99%
2017	-72.24%
2016	-72.51%
2015	-48.63%
2014	0.00%

Jahr

Leistung

2023

-94.17%

2022

-93.06%

2021

-56.86%

2020

-78.77%

2019

-87.10%

2018

1.99%

2017

-72.24%

2016

-72.51%

2015

-48.63%

2014

0.00%

Unternehmen	Aktienkurs	Veränderung 1J%	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$527.87	33.33%	US
Argenx SE ARGX.US	$873.57	35.10%	NL
Lonza Group AG LONN.SW	$736.38	7.69%	CH
UCB S.A. UCB.BR	$263.09	18.09%	BE
Samsung Biologics Co.,Ltd. 207940.KS	$1.08K	-7.22%	KR

Unternehmen

Aktienkurs

Veränderung 1J%

Land